Oncotelic Therapeutics (OTLC) Company Report

On January 23, 2026, Oncotelic Therapeutics, Inc. entered into a Securities Purchase Agreement with Mast Hill Fund, L.P..
Under the agreement, the company issued a senior secured promissory note with an aggregate principal amount of $398,333.33 and an actual purchase price of $358,500.00. The note bears an interest rate of 10% per annum and matures 12 months from its issue date of January 23, 2026.
As additional consideration, the company issued a common stock purchase warrant to acquire 1,422,613 shares of Common Stock at an initial exercise price of $0.15 per share, and 1,600,446 shares of Common Stock (Commitment Shares).
The note is convertible into shares of Common Stock, and the company acknowledges the potentially dilutive effect of the Conversion Shares and Exercise Shares on its Common Stock.

Jan 29, 2026, 9:30 PM

Oncotelic Therapeutics Completes Final Tranche of Unregistered Equity Offering

OTLC

Debt Issuance

Convertible Preferred Issuance

On December 31, 2025, Oncotelic Therapeutics, Inc. completed the third and final tranche of an offering, issuing a total of 44 units to 22 accredited investors.
Each unit consists of a $25,000.00 note bearing 12% annual interest, convertible into 250,000 shares of Oncotelic Common Stock at $0.10 per share or 25,000 shares of EdgePoint Common Stock at $1.00 per share.
Additionally, each unit includes 250,000 warrants to purchase Oncotelic Common Stock at $0.12 per share or 25,000 EdgePoint Warrants to purchase EdgePoint Common Stock at $1.25 per share.
This transaction represents an unregistered sale of equity securities, exempt from registration requirements under Section 4(a)(2) of the Securities Act.

Jan 6, 2026, 9:30 PM

Oncotelic Therapeutics, Inc. Completes Unregistered Sale of Equity Securities

OTLC

Debt Issuance

Convertible Preferred Issuance

On December 23, 2025, Oncotelic Therapeutics, Inc. completed an unregistered sale of 32 units to 21 accredited investors as part of an offering of up to 500 units.
Each unit consists of a $25,000.00 note bearing 12% annual interest, due in two years, and warrants.
The notes are convertible into up to 250,000 shares of Oncotelic Common Stock at $0.10 per share or 25,000 shares of EdgePoint Common Stock at $1.00 per share.
Additionally, investors can convert their EdgePoint shareholding into Oncotelic shares at a rate of 10 shares of Oncotelic Common Stock for every 1 share of EdgePoint.

Dec 30, 2025, 10:00 PM

Oncotelic Therapeutics Announces Private Placement Offering of Convertible Notes and Warrants

OTLC

Debt Issuance

New Projects/Investments

Oncotelic Therapeutics, Inc. is conducting a private placement offering of up to 500 units at $25,000 per unit, with potential gross proceeds of up to $12,500,000.
Each unit includes a $25,000 note bearing 12% annual interest and maturing two years from the final closing date of the Offering. These notes are convertible into 250,000 shares of Oncotelic Common Stock at a conversion price of $0.10 per share or 25,000 shares of EdgePoint AI, Inc. Common Stock at a conversion price of $1.00 per share.
Each unit also includes 250,000 warrants to purchase Oncotelic Common Stock at an exercise price of $0.12 per share, or 25,000 warrants to purchase EdgePoint AI, Inc. Common Stock at an exercise price of $1.25 per share. These warrants are exercisable for two years after issuance.
J.H. Darbie & Co., Inc. serves as the exclusive placement agent, receiving a $25,000 nonrefundable fee, 2% of gross proceeds from sales to its customers for ongoing due diligence, 13% of gross proceeds from sales to its customers as a fee, and warrants to purchase 10% of the aggregate number of units sold.

Dec 9, 2025, 10:01 PM

Oncotelic Therapeutics Announces Phase 1 Clinical Trial Approval for Sapu-003

OTLC

New Projects/Investments

Product Launch

Oncotelic Therapeutics Inc. announced the advancement of Sapu-003, a novel IV formulation of everolimus, which has received approval to start a Phase 1 clinical trial for breast cancer.
Sapu-003, built on the proprietary Deciparticle™ platform, is designed to deliver 100% of the drug directly to the tumor, aiming to improve bioavailability and reduce gastric toxicity compared to oral Afinitor®.
The company targets the breast cancer market, estimated at $30–40 billion and projected to grow to $50 billion by 2030.
Oncotelic anticipates an accelerated development timeline for Sapu-003, aiming for drug approval within 2–3 years, which is significantly faster than traditional drug development.

Oct 22, 2025, 12:00 PM

Oncotelic Therapeutics' Joint Venture Sapu Nano Initiates Phase 1 Clinical Trial for Sapu-003

OTLC

New Projects/Investments

Product Launch

Sapu Nano, a company formed through a joint venture involving Oncotelic Therapeutics, Inc. (OTLC), announced the initiation of a Phase 1 clinical study in Australia for Sapu-003.
Sapu-003 is a novel intravenous Deciparticle™ Everolimus, an mTOR inhibitor, intended to overcome limitations of oral everolimus in treating advanced HR+/HER2– breast cancer and other mTOR-sensitive tumors.
The trial is now open for enrollment at Australian oncology centers, conducted in collaboration with SOCRU, Ingenū, and Medicilon.
Oncotelic Therapeutics holds a 45% ownership stake in GMP Bio, which is part of the Sapu family of companies.

Oct 8, 2025, 12:30 PM

Oncotelic Therapeutics' Joint Venture Subsidiary Sapu Nano Receives Approval for Sapu003 Clinical Trial

OTLC

New Projects/Investments

Sapu Nano, a subsidiary of a joint venture involving Oncotelic Therapeutics (OTLC), has received approval from the Australian Human Research Ethics Committee (HREC) to begin patient recruitment for a Phase 1 human clinical trial of Sapu003.
Sapu003 is an injectable Everolimus formulation developed to treat breast cancer, designed to overcome the limitations of the oral Afinitor® (Everolimus) by achieving 100% bioavailability through intravenous injection, compared to approximately 10% absorption of the oral form.
This novel intravenous delivery method, utilizing Sapu Nano's proprietary Deciparticle™ technology, aims to deliver Everolimus with full efficacy, potentially leading to more significant tumor shrinkage and improved long-term disease control for breast cancer patients than current oral treatments.

Sep 30, 2025, 12:00 AM

Oncotelic Therapeutics Highlights Clinical and Regulatory Advancements

OTLC

New Projects/Investments

Oncotelic Therapeutics (OTLC) summarized two years of significant clinical progress and regulatory validation across its late-stage pipeline, as of September 12, 2025.
Key pipeline advancements include OT-101 in Phase 3 for pancreatic cancer, OXi4503 in Phase 2 for AML/MDS and advancing toward Phase 3 design, and AL-101 in Phase 2 for Parkinson's disease and sexual dysfunctions.
The company is also advancing pediatric rare disease programs with potential for Priority Review Vouchers and a nanomedicine pipeline utilizing the 505(b)(2) pathway.
Oncotelic Therapeutics holds a 45% ownership stake in GMP Bio, a joint venture led by its CEO, Dr. Vuong Trieu, which expands its portfolio in oncology and rare diseases.